Loading
Life sciences · Journal article
Journal of Obesity & Metabolic Syndrome · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Obesity drives metabolic syndrome and cardiometabolic disease in Asia, where complications develop at lower levels of adiposity than in Western populations. We reviewed Asian obesity policies to identify design features that support their durability and how access to incretin-based medications fits within these policies. Methods: This narrative review used a structured search of PubMed/MEDLINE and Embase (January 2000 to March 2025) supplemented by grey literature from public health agencies. Of 1,884 records, 612 underwent full-text review and 236 met inclusion criteria. Two reviewers screened independently, resolving disagreements by consensus. Evidence was grouped into healthcare-based prevention and treatment, fiscal and regulatory measures, food and physical activity environments, digital health, and pharmacotherapy access. Results: We examined Japan's Specific Health Checkup, Korea's National Health Screening Program, Singapore's Nutri-Grade scheme, and sugar-sweetened beverage taxes in Thailand, Malaysia, and the Philippines. Three design principles emerged: holding insurers accountable for population metabolic screening, scheduling excise tax increases in advance, and adapting regulation to local food settings, including freshly prepared foods. Their effectiveness was limited by stigma in workplace screening, limited reach into the informal food sector, and lower uptake in rural and digitally underserved populations. Policy durability depended more on governance than on individual measures. Conclusion: Obesity policy in Asia requires governance mechanisms built into its design: a permanent inter-agency body with protected funding, legal safeguards against industry interference, and mandatory equity audits with independent monitoring. Access to incretin-based medications belongs in the same framework; otherwise, these drugs may widen regional inequities.